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Background
Hypertrophic Cardiomyopathy (HCM) is characterized by
asymmetric hypertrophy of the left ventricle (LV). While
over 400 HCM mutations have been identified, increasing
number of HCM mutation carriers without hypertrophy
have been detected. No data on regional functional and
structural abnormalities in HCM mutation carriers before
the development of hypertrophy are yet available. With
cardiac magnetic resonance imaging (CMR), both
regional function and structure can accurately be evalu-
ated.
Methods
28 HCM mutation carriers from 9 different families and
28 age- and gender matched controls, of whom 15 were
genotype negative family members of HCM mutation car-
riers, underwent CMR. The imaging protocol included full
coverage of the LV and left atrium with cine imaging. Sub-
sequently, three short axis slices at basal, mid and apical
level were obtained with myocardial tissue tagging (tem-
poral resolution 14 ms, tag persistence >1000 ms).
Finally, delayed contrast enhancement imaging was per-
formed. From these datasets, global LV dimensions and
left atrial volumes, end-diastolic wall thickness, septal-to-
lateral-wall-thickness ratio (SL-ratio), wall thickening,
peak systolic circumferential strain (peak SCS), peak
systolic circumferential strain rate (peak SCSR), peak
diastolic circumferential strain rate (peak DCSR) were
determined.
Results
Global LV dimensions were comparable between both
groups. No contrast enhancement was found. Crypts were
present in the inferoseptum in 23 of 28 HCM mutation
carriers (82%) and in none of the controls. SL-ratio was
larger in HCM mutation carriers than in controls (1.3 ±
0.21 versus 1.1 ± 0.13, p < 0.001), see Figure 1. In HCM
mutation carriers, wall thickening in inferoseptal seg-
ments at basal and mid level was lower compared to con-
trols (0.61 ± 0.31 versus 0.77 ± 0.26, p < 0.01).
Peak SCS was comparable in the septum (-16.8 ± 3.0 ver-
sus -16.4 ± 2.7, p = ns) which may result from pseudonor-
malization due to the regional crypt formation. Peak SCS
was lower in the lateral segments in HCM mutation carri-
ers compared to controls (-17.7 ± 3.4% and -19.9 ± 3.4%,
p < 0.05). Peak SCSR was lower in the basal inferoseptal
and lateral segments in HCM mutation carriers compared
to controls (-107 ± 14.0%.s-1 versus -119 ± 18.7%.s-1, p <
0.05). Peak DCSR was lower in all segments in HCM
mutation carriers compared to controls (mean 99.2 ±
28.79%.s-1 versus 114 ± 33.2%.s-1, p < 0.001). With
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increase of end-diastolic wall thickness, peak SCS and
peak SCSR were maintained, while peak DCSR decreased
see Figure 2. In line with the observed decrease in peak
DCSR, a marker of diastolic dysfunction, left atrial maxi-
mum volume was larger in HCM mutation carriers com-
pared to controls (56 ± 11.7 versus 51 ± 6.4 ml.m-2, p <
0.05).
Conclusion
Functional abnormalities, characterized by reduced systo-
lic and diastolic strain and strain rate are present in HCM
mutation carriers without manifest hypertrophy. In addi-
tion, these patients exhibit structural abnormalities
including septal to lateral asymmetry in left ventricular
wall thickness and the presence of crypts. These structural
abnormalities and decreased regional peak DCSR may
thus be recognized as important, early identification of
asymptomatic HCM mutation carriers.
Figure 2
Systolic and diastolic dysfunction and subsequent left atrial dila ion re pre ent in hypertr phic cardiomyopathy mut -tion carriers b fore the development of overt hyp rtrophyFigure 1
Systolic and diastolic dysfunction and subsequent left atrial 
dilation are present in hypertrophic cardiomyopathy muta-
tion carriers before the development of overt hypertrophy. 
Asymmetric wall thickening is associated with crypt forma-
tion with occurs in 82 percent of hypertrophic cardiomyopa-
thy mutation carriers.Page 2 of 2
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